baber/WOPTO huggingface dataset:
Patent NZ-208426-A (NZ)
Title: Addressable catv converter: setting secure address into converter memory
Inventor: O'BRIEN T E
IPC: H04N7/16
Filed: 1984-06-08
Abstract: An addressable CATV converter for connection with a remote headend in a cable distribution system contains a memory into which a unique address code identifying that converter is downloaded from the remote headend.
Patent NZ-217369-A (NZ)
Title: Heat pack device: supercooled solution contains filamentary, metallic, activator
Inventor: SMITH MARTIN L
IPC: F24V30/00
Filed: 1986-08-27
Abstract: PCT No. PCT/GB86/00506 Sec. 371 Date Apr. 21, 1987 Sec. 102(e) Date Apr. 21, 1987 PCT Filed Aug. 26, 1986 PCT Pub. No. WO87/01275 PCT Pub. Date Mar. 12, 1987.A trigger device for a heat pack comprises three helically-coiled, resilient metallic filaments (1,2,3) nested one within the other and of inwardly decreasing diameter, the filament (2) being wound in a sense opposite to that of filaments (1) and (3). Flexing the assembly of nested helices about its longitudinal axes produces a rubbing action action between adjacent turns thereof which initiates crystallization. Other devices comprises two nested helices wound in the same sense; a single helix having a pressure plate at one end and an external or internal cap at the other; and a body of randomly convoluted or woven metallic filament.
Patent NZ-223670-A (NZ)
Title: Antidepressant compositions comprising a tricyclic antidepressant compound and a n-benzyl-pyrrolidin-2-one derivative
Inventor: LEHR ERICH
IPC: A61K31/44
Filed: 1988-02-26
Abstract: An agent containing a compound A and a compound B having synergistic activity as an antidepressive.
Patent NZ-226316-A (NZ)
Title: Pharmaceutical contraceptive preparations and packages containing from 20-35 unit dosages comprising an estrogen and a progestin; the unit dosages having alternating estrogen and progestin dominance
Inventor: CASPER ROBERT F
IPC: A61P5/24
Filed: 1988-09-23
Abstract: This invention is concerned with a contraceptive formulation and a method of contraception which employs a combination of estrogen and progestin and wherein a short period of relatively dominant estrogenic activity alternates with a short period of relatively dominant progestagenic activity. The invention also concerns a hormonal replacement formulation and method for use in menopausal or castrate women which employs a similar combination of estrogen and progestin.
Patent NZ-234217-A (NZ)
Title: Thin walled metal container with necked-in end
Inventor: CALEFFI ANTONIO
IPC: B65D1/40
Filed: 1988-02-05
Abstract: A die necking method and apparatus for producing a smooth tapered wall between the container side wall and a reduced diameter neck includes a plurality of rotatable necking turrets that each have a plurality of identical necking substations each having a necking die. The necking dies in the respective turrets have an internal configuration to produce a necked-in portion on the container which has a first arcuate segment integral with the container side wall and a second arcuate segment integral with the reduced diameter neck. The necking substations also have a floating form control element that engages the inner surface of the container to control the portion of the container to be necked. The necked-in portion is reformed in each succeeding turret by dies to produce a smooth tapered wall between the arcuate segments.
Patent NZ-238160-A (NZ)
Title: Gas-filled microcapsules/microballoons for ultrasonic echography
Inventor: BICHON DANIEL
IPC: A61K9/127
Filed: 1991-05-16
Abstract: Air or gas filled microballoons bounded by an interfacially deposited polymer membrane which can be dispersed in aqueous carrier liquids to be injected into living organisms or administered orally, rectally and urethrally for therapeutic or diagnostic purposes (echography). The properties of the polymeric membrane of the microballoons (elasticity, permeability, biodegradability) can be controlled at will depending on the selected polymer, the interfacial deposition conditions, and the polymer additives.
Patent NZ-247703-A (NZ)
Title: Thienobenzdiazepine derivatives and medicaments thereof
Inventor: FAIRHURST JOHN
IPC: A61K31/551
Filed: 1993-05-26
Abstract: Pharmaceutical compounds of the formula <CHEM> in which R<1> is hydrogen or halo, and R<2> is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl optionally substituted by 1 to 3 C1-4 alkyl groups, C3-6 cycloalkyl-C1-4 alkyl in which the cycloalkyl group is optionally substituted by 1 to 3 C1-4 alkyl groups, or optionally substituted phenyl-C1-4 alkyl; or a salt thereof.
Patent NZ-251628-A (NZ)
Title: Aqueous insectable rapamycin solution; product containing concentrate and diluent solutions
Inventor: WARANIS ROBERT PAUL
IPC: A61K31/70
Filed: 1993-03-29
Abstract: Disclosed herein is an aqueous, injectable rapamycin solution comprising 0.1 to 10 percent of a concentrate solution of rapamycin in N,N-dimethylacetamide, at concentrations of rapamycin ranging from 0.25 mg/ml to 100 mg/ml, in combination with a diluent solution consisting of 0.1 to 10 weight percent of one or more polyoxyethylene sorbitan esters, 10 to 60 weight percent of either polyethylene glycol 200 or 300 or both and 30 to 90 volume percent water, wherein the concentration of rapamycin in he combined solution ranges from 0.05 mg/ml to 5.0 mg/ml. Also disclosed is an aqueous, injectable solution of rapamycin, said solution comprising rapamycin in 0.1 to 10 weight percent N,N-dimethylacetamide, 0.09 to 7.5 weight percent of one or more polyoxyethylene sorbitan esters, 9 to 60 weight percent of either polyethylene glycol 200 or 300 or both and 30 to 90 volume percent of water, wherein the concentration of rapamycin in the solution ranges from 0.05 mg/ml to 5.0 mg/ml. Preferred aqueous, injectable rapamycin solutions are those wherein one polyoxyethylene sorbitan ester is present and the polyethylene glycol present is polyethylene glycol 300.
Patent NZ-282800-A (NZ)
Title: Heat exchanger tube; two piece ribbed aluminium insert within cylindrical steel outer tube
Inventor: KUNKEL WOLFGANG
IPC: F28F13/06
Filed: 1995-03-15
Abstract: PCT No. PCT/EP95/00957 Sec. 371 Date Sep. 16, 1996 Sec. 102(e) Date Sep. 16, 1996 PCT Filed Mar. 15, 1995 PCT Pub. No. WO95/25937 PCT Pub. Date Sep. 28, 1995The heat exchanger tube comprises a cylindrical, smooth walled outer tube (1) of steel into which a profiled insert (2) of aluminium is inserted. The profiled insert is constituted by two half shells (3,4) which engage in one another at their longitudinal edges with groove-shaped recesses (7) and rib-like projections (8). Both half shells (3,4) carry longitudinally extending ribs (5) on their internal surface which are so aligned that each half shell with its ribs constitutes a profile which is open on one side.
Patent NZ-301916-A (NZ)
Title: Monoclonal antibodies to il-5 for use as antagonists to il-5 related disorders
Inventor: AMES ROBERT S
IPC: C12N15/09
Filed: 1995-12-22
Abstract: PCT No. PCT/US95/17082 Sec. 371 Date Jun. 19, 1997 Sec. 102(e) Date Jun. 19, 1997 PCT Filed Dec. 22, 1995 PCT Pub. No. WO96/21000 PCT Pub. Date Jul. 11, 1996Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
Patent NZ-328017-A (NZ)
Title: xanthine compounds; medicaments
Inventor: GEBERT ULRICH
IPC: A61K31/52
Filed: 1997-06-05
Abstract: Use of a compound of formula (I) in the manufacture of medicament for the treatment and/or prophylaxis of shock disorders, wherein: R1 is a straight-chain or branched alkyl group, alkoxy-alkyl, phenyl or phenyl-alkyl in which the phenyl radicals are optionally substituted by one or two halogen atoms; A is a straight-chain or branched alkylene group; and R2 is a straight-chain or branched alkyl, cycloalkyl, cycloalkyl-alkyl, phenyl or phenyl-alkyl.
Patent NZ-331794-A (NZ)
Title: Compositions comprising crystalline-like transition metal material and methods of use thereof
Inventor: PATALANO PHILIP
IPC: G03G5/16
Filed: 1997-03-25
Abstract: Described are devices comprising and methods of use containing photomagnetic material that increases local magnetization after being irradiated with light. These may be optical computers, computer disks, both with read-write capability and random access memory, light weight motors, magnetic and analog films, tapes or substrates, digital films, tapes or substrates, optical switches, photocopiers and sensors. The method for recording information on a magnetic medium where: a) placing the magnetic medium in an applied magnetic field b) applying light to first location to induce magnetization so that the magnetization increases the strength of the magnetic field at the first location by a first amount to change the polarization of the first magnetically polarized local domain.
Patent NZ-334309-A (NZ)
Title: Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
Inventor: YU GUO-LIANG
IPC: C12N1/21
Filed: 1996-10-25
Abstract: The specification describes a Neutrokine a protein which is a member of the TNF protein family.  In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine a protein including soluble forms of the extracellular domain.  Neutrokine a polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The specification describes screening methods for identifying agonists and antagonists of Neutrokine a activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
Patent NZ-335771-A (NZ)
Title: Heat-exchange coil assembly comprising coils communicating an inlet to an outlet header, with coils of different diameters being connected to alternate sides of headers
Inventor: MARUYAMA NORORU
IPC: F28D7/02
Filed: 1999-05-14
Abstract: A heat-exchange coil assembly comprising:  A medium inletting member having an inlet tube and an intlet header each for inletting a heat-exchange medium;  A medium out-letting member having an outlet tube and an outlet header each for out-letting a heat-exchange medium;  A plurality of heat-exchange coils each communicating the inlet header to the outlet header and giving a different winding diameter; wherein the heat-exchange coils have a common center line and are alternately linked to opposite sides of the center line of the headers.  Fluid flows via inlet tube [3], header [2] and then through coils [8-1]-[8-5] to outlet header/tube [5].
Patent NZ-336937-A (NZ)
Title: Infectious bursitis vaccine comprising an Infectious Burstitis virus capable of protecting poultry
Inventor: DAVELAAR FRANS GERRIT
IPC: A61K35/76
Filed: 1998-01-29
Abstract: A vaccine that is capable of protecting poultry against Infectious Bursitis infections is described.  It is characterised in that it contains an Infectious Bursal Disease Virus (IBDV), which has the combined properties of, when administered to a chicken, causing a reduction in the size of the bursa, expressed as bursa/body weight ratio of less than 55 %, and the capability to protect poultry having an ELISA antibody titer of at least 500.
Patent NZ-337562-A (NZ)
Title: Relating to a self-hydrating container adapted for production of fermented milk products
Inventor: MARSHALL COLIN
IPC: A01J11/06
Filed: 1998-03-13
Abstract: A self-rehydrating container for yoghurt production comprising a semi-permeable membrane which allows the preparation of substantially sterile water solutions using osmotically driven filtration, containing a carbohydrate, a fermented milk product forming starter culture, milk powder and eventually other milk edible solutes. The self-rehydrating container is characterised in that the carbohydrate is selected from the group consisting of lactose, sucrose and dextrose.
Patent NZ-501665-A (NZ)
Title: Porting user number between networks utilising a temporary number in the new network
Inventor: TILANUS PAULUS ANTHONIUS JOSEP
IPC: H04Q3/00
Filed: 1998-06-17
Abstract: In the method for porting a telephone number (N) related to a user of a terminal (4) of a first network (1) to a second network (2), the number (N) is activated in the second network (2) and the number (N) is deactivated in the first network (1).  Before or at the point in time of activating the number (N) in the second network (2), a further number (T) is activated for the user in the second network (2). Subsequently, call forwarding of the number (N) in the first network (1) is activated to the further number (T) in the second network (2), and thereafter the user is coupled to the second network (2). This method allows the user to remain permanently reachable during the number portability procedure.
Patent NZ-508190-A (NZ)
Title: Apparatus for detecting mastitis with test fluid dispenser and receptacle in one device
Inventor: HILHORST BERNARD FRANCIS
IPC: B01L3/00
Filed: 2000-11-16
Abstract: Upon activation an amount of test fluid is dispensed into a receptacle and mixed with the sample to produce a visual indication of mastitis.
Patent NZ-508269-A (NZ)
Title: Protein formulations
Inventor: BILLGER MARTIN
IPC: A61K38/00
Filed: 1999-04-26
Abstract: The present invention relates to pharmaceutical formulations comprising human parathyroid hormone at a concentration from 0.3 to 10 mg/ml, a pharmaceutically acceptable buffer having a pH from 4 to 6, and at least one tonicity modifier. The said pharmaceutical formulations are useful for the treatment of bone related disorders such as osteoporosis.
Patent NZ-510931-A (NZ)
Title: Polylactide-polyglycolide (PLGA) sustained release formula containing at least 50% active ingredient
IPC: A61K31/765
Filed: 1997-12-02
Abstract: A solid delayed-release formulation, intended to be placed in a body, containing at least one active principle and a biodegradable excipient, wherein the excipient is a polyactide-glycolide (PLGA) copolymer, the concentration of the active principle is over 40% and the excipient does not form a matrix containing the active principle, whereby the release profile of the active principle is constant and the duration of release is substantially greater in vivo than in physiological aqueous medium in vitro.  A process of preparation of this delayed-release formulation is also described.
Patent NZ-512976-A (NZ)
Title: Pyrazole derivatives useful as nitrification inhibitors
Inventor: RITTINGER STEFAN
IPC: C05G3/90
Filed: 1997-08-06
Abstract: A pyrazole derivative is useful as a nitrification inhibitor is selected from: N-hydroxymethyl-4-chloro-3-methylpyrazole, N-hydroxymethyl-3,4-dimethyl pyrazole, Phosphoric acid addition salt of 3,4-dimethylpyrazole, Phosphoric acid addition salt of 4-chloro-3-methylpyrazole, and Hydrochloride of 3,4-dimethylpyrazole. An inorganic fertilizer comprising at least one pyrazole derivative is also described.
Patent NZ-516000-A (NZ)
Title: A teatcup liner, a teatcup and a milking member
Inventor: AELVEBY NILS
IPC: A01J5/08
Filed: 2000-06-09
Abstract: The invention refers to a teatcup liner, a teatcup and a milking member. The teatcup liner (1) is mountable in a teatcup shell (2), having a first end (3) and a second end (4), in such a manner that it in the mounted state extends through the teatcup shell (2) and forms an inner space (5) to a teat and an outer space (6) between the teatcup shell and the teatcup liner. The teatcup liner (1) includes an opening for introducing a teat into the inner space. The opening is located at the first end. The teatcup liner also includes a grip area (10), which is arranged to be gripped by a grip portion (11) of the teatcup shell in such a way that the grip area is surrounded by and abuts the grip portion. The grip area (10) has, seen in a cross section, a non-circular shape. The teatcup liner (1) has a connection portion (20) for being connected to a teatcup claw (9). The connection portion includes means (22) arranged to define a rotary position for the teatcup liner (1) in relation to the teatcup claw (9).
Patent NZ-516553-A (NZ)
Title: 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2 and its preparation method
Inventor: REDDY E PREMKUMAR
IPC: A61K31/415
Filed: 2000-06-16
Abstract: 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines of formula (I) and their salts that are inhibitors of cyclooxygenase-2 activity are disclosed, wherein: X is selected from the group consisting of trihalomethyl, C1-C6 alkyl, and a group of formula (II); wherein R3 and R4 are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C1-C6 alkyl; C1-C6 alkoxy; carboxy; C1-C6 trihaloalkyl; and cyano; and Z is selected from the group consisting of substituted and unsubstituted aryl; provided: that when X is either trihalomethyl or C1-C6 alkyl or a group of formula (II) then Z has a different meaning (in terms of substituent groups) corresponding to each of X as defined in the specification. 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines of formula (I) and their salts are useful for treating cyclooxygenase-mediated disorders, including, for example, inflamation, neoplastic disorders and angiogenesis-mediated disorders.
Patent NZ-518877-A (NZ)
Title: Selectable cell surface marker genes
Inventor: PIPPIG SUSANNE DAGMAR
IPC: C12Q1/02
Filed: 2000-11-17
Abstract: A method of identifying genetically modified mammalian cells comprising: a) introducing a nucleic acid sequence encoding a mutated protein-tyrosine kinase receptor (PTKR) operatively linked to an expression control sequence in to a cell to form a genetically modified cell, wherein the mutated PTKR either comprises a modification to the intracellular and the extracellular domains, or excludes any nerve growth factor receptors(s) (NGFR) and comprises a modification to the intracellular domain; b) allowing expression of the mutated PTKR in the genetically modified cell; and c) identifying said genetically modified cell expressing the mutated PTKR; provided that if the cell is human, the method is performed ex vivo. Also disclosed is the use of said method in the immunoselection of transduced mammalian cells, and mutated muscle specific tyrosine (MuSK-R) family members which are truncated in the cytoplasmic domain for use in said method.
Patent NZ-523436-A (NZ)
Title: Indole derivatives useful for the treatment of CNS discorders
Inventor: FELDING JAKOB
IPC: A61K31/5377
Filed: 2001-07-17
Abstract: A substituted indole derivative of formula I where: - R1 is hydrogen or C1-6 alkyl, C-2-6 alkenyl, C2-6alknyl, C3-8cycloalkyl or C3-8cycloalkyl-C1-6-alkyl, all of which may be substituted one or more times with substituents selected from halogen, cyano, nitro, amino, hydroxy, thiol, C1-6-alkoxy, C1-6-alkylthio, trifluoromethyl, trifluoromethylsulfonyl and C1-6alkylsulfonyl, or R1 is aryl, aryl-C1-6-alkyl, heteroaryl, or heteroaryl-C1-6-alkyl where the aryl and heteroaryl groups may be substituted one or more times with substituents selected from halogen, cyano, nitro, amino, C1-6alkylsulfonyl, or R1 is -NR'R" where R' and R" are independently selected from hydrogen and C1-6alkyl, aryl, aryl-C1-6alkyl, heteroaryl and heteroaryl-C1-6alkyl, all of which may be substituted one or more times with substituents selected from halogen, cyano, nitro, amino, C1-6alkyl, C1-6alkoxy, C1- 6alkylsulfonyl, or R1 is a saturated 5- to 6- membered ring containing one, two or three hetero atoms selected from O, S and a group N-R9 wherein R9 is hydrogen or C1-6alkyl optionally substituted with substituents selected from halogen, cyano, nitro, amino, C1-6-alkoxy, C1-6-alkylthio, hydroxy, thiol, trifluoromethyl, trifluoromethylsulfonyl and C1- 6alkylsulfonyl; - W is a bond or an O, S, CO, CS, SO or SO2 group; - n and m is 0-6, and m + n is 0-6; provided that when W is O or S, 2 </= n, and when W is CO, CS, SO or SO2, 1</= n - X is C, CH or N and the dotted line emanating from X indicates a bond when X is C and no bond when X is N or CH; - R2 is C1-6 alkyl; - R3-7 are independently selected from hydrogen, halogen, cyano, nitro, amino, C1-6-alkyl, C2-6alkenyl, C2-6alkynyl, C3- 8-cycloalkyl, C3-8-cycloalkyl-C1-6-alkyl, C1-6-alkoxy, C1-6alkylthio, hydroxy, thiol, trifluoromethyl, trifluoromethylsulfonyl and C1-6alkylsulfonyl; and - R8 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-6alkyl, aryl, aryl-C1-6alkyl, acyl, thioacyl, C1-6alkylsulfonyl, trifluoromethylsulfonyl or arylsulfonyl. A compound of formula I as described above may be used for treating: - positive and negative symptoms of schizophrenia, other psychosis, anxiety disorders, depression, aggression, side effects induced by conventional antipsychotic agents, migraine, cognitive disorders, or ADHD, or in the improvement of sleep.
Patent NZ-525544-A (NZ)
Title: Geothermal power generation
Inventor: HALFF ALBERT H
IPC: F03G7/04
Filed: 2001-07-25
Abstract: A geothermal power generation system having an input well (1) extending from the surface (3) into a hot rock strata (4) and an output well (5) spaced away from an input well extending from the surface into the hot rock strata. The input and output wells extend into the hot rock strata. A horizontal bore (6) connects the two wells together. The bore is located in the hot rock strata and consists of a casing alone or a casing and a backfill between the casing and the hole. Alternatively, the system may consist of only one vertical well and a horizontal bore extending into the hot rock strata and a pipe that returns the water into the horizontal bore.
Patent NZ-527337-A (NZ)
Title: Ionic molecular conjugates of bio degradable polyesters and bioactive polypeptides
IPC: C08G63/64
Filed: 2000-01-26
Abstract: A polyester containing one or more free COOH groups and having a carboxyl to hydroxyl ratio greater tan one, wherein the polyester contains a member selected from the group consisting of L-lactic acid, D-lactic acid, DL-lactic acid, malic acid, citric acid, tartaric acid, å-caprolactone, p-dioxanone, å-caproic acid, alkylene oxalate, cycloalkylene oxalate, alkylene succinate, â-hydroxybutyrate, substituted or unsubstituted trimethylene carbonate, 1,5-dioxepan-2-one, 1,4-dioxepan-2-one, glycolide, glycolic acid, L-lactide, D-lactide, DL-lactide, meso-lactide, and any optically active isomers, racemates or copolymers thereof, provided that tartaric acid is a member of the polyester and further provided that the polyester is not poly-L-lactic-co-glycolic-co-L-tartaric acid.
Patent NZ-527365-A (NZ)
Title: N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
Inventor: CLAIBORNE CHRISTOPHER F
IPC: C07D401/12
Filed: 2002-02-20
Abstract: Disclosed are compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein NonAr is a nonaromatic 5-7 membered ring containing 1 or 2 nitrogen ring atoms or an aza bicyclo octane ring; HetAr is a 5 or 6 membered heteroaromatic ring containing 1-3 nitrogen ring atoms, or isoxazolyl, thiazolyl, thiadiazolyl, quinolinyl, quinazolinyl, purinyl, pteridinyl, benzimidazolyl, pyrrolopyrimidinyl, or imidazopyridinyl; HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C1-4alkyl, C1-4alkoxy, C2-4alkynyl, trifluoromethyl, hydroxy, hydroxyC1-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-, -N(C0-4alkyl)(C0-4alkyl), nitro, (C1-2alkyl)(C1-2alkyl)NCH2-, (C1-2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-; A is -C-0-4alkyl-; B is aryl(CH2)0-3-O-C(O)-, heteroaryl(CH2)----1-3--O-C(O)-, indanyl(CH2)---0-3--O-C(O)-, aryl(CH2)1-3-C(O)-, aryl-cyclopropyl-C(O)-, heteroaryl-cyclopropyl-C(O)-, heteroaryl(CH2)1-3,-C(O)-, heteroaryl(CH2)1-3, aryl(CH2)1-3-NH-C(O)-, aryl(CH2)1-3-NH-C(NCN)-, aryl(CH2)1-3-SO2-, heteroaryl(CH2)1-3-SO2-, wherein any of the aryl or heteroaryl is optionally substituted by 1-5 substituants, each substituent independently is C1-4alkyl, C3-6cycloalkyl, C1-4alkoxy, trifluoromethyl, bromo, fluoro or chloro; and X is H, OH, F, C1-4alkyl C1-4alkoxy, NH2, or X taken with an adjacent bond is =O. Further disclosed is the use of compounds of the formula (I) in the preparation of a medicament for the treatment of pain, migraine, depression, schizophrenia, Parkinson's disease, or stroke.